Literature DB >> 23550446

[Histology and molecular biology of GIST].

Jean-François Emile1.   

Abstract

Gastrointestinal stromal tumors (GIST) are the most frequent sarcomas but were underdiagnosed until the beginning of this century. GIST derive from interstitial cells of Cajal and may develop all along the digestive tract. GIST are characterized by the expression of KIT (CD117), and also DOG-1, which was recently discovered by transcriptome analysis. Gain-of-function mutations of the tyrosine kinase receptors KIT and PDGFRA are present in 85% of cases. More than 150 different mutations have been reported, mostly located in exon 11 of the KIT gene. Detection of these mutations may be useful to confirm the diagnosis and to evaluate the prognosis. Mutations also have predictive value. For example, patients with metastatic GIST and a duplication of KIT exon 9 should receive twice the usual dose of imatinib, while GIST with the PDGFRA p. D842 V mutation are resistant to imatinib. This article presents the main pathologic characteristics of GIST and the important insights that GIST research has provided for oncology in general.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23550446

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  3 in total

1.  Expression of L1 protein correlates with cluster of differentiation 24 and integrin β1 expression in gastrointestinal stromal tumors.

Authors:  Yue DU; Haihong Zhang; Zhongmin Jiang; Guowei Huang; Wenli Lu; Hesheng Wang
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

2.  Uterine leiomyoma mimicking a gastrointestinal stromal tumor with chronic spontaneous hemorrhage: A case report.

Authors:  Xiaoqing Zhu; Jing Fei; Weijiang Zhang; Jianwei Zhou
Journal:  Oncol Lett       Date:  2015-03-27       Impact factor: 2.967

3.  Laparoscopic treatment of large gastrointestinal stromal tumors (> 5 cm).

Authors:  Maciej Stanek; Magdalena Pisarska; Anna Rzepa; Dorota Radkowiak; Piotr Major; Andrzej Budzyński
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-10-15       Impact factor: 1.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.